Toric Trifocal IOL Treatment With High Astigmatism & Hyperopia vs SMILE

Status Completed

Clinical Trial Summary

The aim of this study is to assess visual and refractive outcomes after Toric Trifocal lens implantation and visual outcomes after laser vision correction (LVC) - ReLex Smile to correct residual refraction after 6 months of Toric Trifocal (IOL) implantation.

Clinical Trial Description

The current state of the art for the correction of aphakia and presbyopia after lens extraction and refractive lensectomy is the implantation of multifocal intraocular lenses (IOL). In this study, the trifocal IOL types AT LISA TRI 839MP and AT LISA TRI TORIC 939MP (Carl Zeiss Meditec, Germany) were assessed. In this prospective non-randomized study patients with spherical hypermetropia of >4 D in combination with high astigmatism of >3.0 D were treated. The first group of 40 eyes of 20 patients underwent refractive lensectomy, followed by implantation of the diffractive trifocal IOL type AT LISA TRI 839MP (Carl Zeiss Meditec, Jena, Germany) and 6 months later SMILE surgery. In 40 eyes of 20 patients in the second group IOL type AT LISA TRI TORIC 939MP were implanted. All patients were adequately consulted preoperatively about this type of IOLs and they were verbally consented. The study is adherent to the tenets of the Declaration of Helsinki. All patient are between 20- 45 years old. The current study demonstrates that both the non-toric and toric versions of the trifocal IOL evaluated here provide excellent functional vision to patients, with good distance, intermediate and near uncorrected VA, a wide range of vision and good contrast sensitivity. Before SMILE,Yag-Laser capsulotomy should be performed on all patients, regardless of posterior capsule ossification, in pseudophakic patients with residual refraction. When the Yag-Laser is applied after the Smile, there will be a diopter change. Relex Smile surgery in pseudophakic patients with trifocal IOL was safe, effective, and predictable in a large cohort of patients. It is noteworthy that the decision for a treatment strategy (toric IOL or non-toric IOL with SMILE in s second step) should be made carefully, to select the appropriate method for the patient. During phaco surgey the positions of incisions should be determined according to the angle of the highest K value of the patient. For high astigmatic patients, toric trifocal IOL is highly effective. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04468022
Study type	Interventional
Source	Eye Hospital Pristina Kosovo
Contact
Status	Completed
Phase	N/A
Start date	June 1, 2018
Completion date	June 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06046209` - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens	N/A
Completed	`NCT05656885` - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses	N/A
Completed	`NCT02423109` - Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses	N/A
Completed	`NCT01392950` - Clinical Study of Clariti Monthly Contact Lens	N/A
Withdrawn	`NCT00765960` - Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure
Completed	`NCT00520689` - Multipurpose Disinfecting Solution Compatibility With a Silicone Hydrogel Contact Lens	Phase 3
Completed	`NCT05538182` - Zimbabwe Eyecare And Learning(ZEAL):Formative Research on Hyperopia and Educational Outcomes in Primary School Children	N/A
Enrolling by invitation	`NCT05976750` - Air Optix® Night and Day® Aqua Daily Wear
Completed	`NCT02575911` - Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study	N/A
Completed	`NCT05735990` - Retrospective Clinical Investigation of the Safety and Performance of 640PM Trifocal IOL Implantation in Patients With Cataract and/or Ametropia (Hyperopia, Myopia) and/or Presbyopia
Withdrawn	`NCT03671096` - Safety and Efficacy of the Transform™ Corneal Allograft for Hyperopia Correction	N/A
Recruiting	`NCT02279446` - Development of a Validated Chart for Intermediate Vision Assessment	N/A
Completed	`NCT01951573` - Evaluation of a New Daily Disposable Multifocal Contact Lens Design	N/A
Completed	`NCT02060539` - Multicenter Dispensing Study of Biofinity Lenses in Extended Range	N/A
Completed	`NCT01467557` - Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY
Completed	`NCT01228591` - Pilot Dispensing Evaluation of a Plus Power Lens	N/A
Completed	`NCT03722784` - Evaluation of Silicone Hydrogel Daily Wear Contact Lenses for Up to One (1) Month of Daily Wear	N/A
Completed	`NCT03688672` - Apioc Contact Lens Feasibility	N/A
Completed	`NCT05741450` - A Clinical Comparison of Two Soft Contact Lenses	N/A
Completed	`NCT01912781` - Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Gas Permeable Contact Lens Wearers	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Toric Trifocal IOL Treatment With High Astigmatism and Hyperopia vs SMILE Enhancement After Trifocal IOL Treatment

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms